NuVasive Inc. may be getting a break on what it needs to shell out to Medtronic PLC for infringement of certain spine device patents.
Court Wants To Reassess Damages In NuVasive/Medtronic Patent Fight
In a long-standing patent fight between NuVasive and Medtronic, an appeals court has ruled NuVasive was being penalized twice for lost profits based on damages awarded by a jury. The judges unanimously agreed to send the case back to a district court to reevaluate how much Medtronic should be paid.
More from Archive
• By
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
• By
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
• By
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.